Cargando…

Patient-reported genitourinary toxicity for long-term prostate cancer survivors treated with radiation therapy

BACKGROUND: The objective of this study is to provide comprehensive overviews of patient-reported urinary symptoms for long-term prostate cancer survivors treated with radiation therapy and for untreated, healthy men. METHODS: We performed a population-based cross-sectional study using a study-speci...

Descripción completa

Detalles Bibliográficos
Autores principales: Olsson, C E, Pettersson, N, Alsadius, D, Wilderäng, U, Tucker, S L, Johansson, K-A, Steineck, G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3670502/
https://www.ncbi.nlm.nih.gov/pubmed/23632483
http://dx.doi.org/10.1038/bjc.2013.180
_version_ 1782271860054949888
author Olsson, C E
Pettersson, N
Alsadius, D
Wilderäng, U
Tucker, S L
Johansson, K-A
Steineck, G
author_facet Olsson, C E
Pettersson, N
Alsadius, D
Wilderäng, U
Tucker, S L
Johansson, K-A
Steineck, G
author_sort Olsson, C E
collection PubMed
description BACKGROUND: The objective of this study is to provide comprehensive overviews of patient-reported urinary symptoms for long-term prostate cancer survivors treated with radiation therapy and for untreated, healthy men. METHODS: We performed a population-based cross-sectional study using a study-specific postal questionnaire assessing symptoms among 1007 men consecutively treated at the Sahlgrenska University Hospital, Göteborg, Sweden from 1993–2006 (primary or salvage external beam radiation therapy (EBRT) or EBRT and high-dose rate brachytherapy). We also randomly recruited 350 non-pelvic-irradiated matched control men from the Swedish Total Population Register. Symptom prevalence and prevalence ratios were computed. RESULTS: Survey participation rate was 89% (874/985) for eligible survivors and 73% (243/332) for eligible controls. Median time from treatment to follow-up was 5 years (range, 1–14 years). Among the 21 investigated symptoms reflecting obstruction, frequency, urgency, pain and incontinence, we found significantly higher prevalence compared with controls for 9 symptoms in the EBRT group, 10 in the EBRT+brachytherapy group and 5 in the salvage EBRT group. The prevalence for a majority of the symptoms was stable over time. CONCLUSION: The presented toxicity profiles provide a thorough understanding of patient-reported urinary symptoms that can assist in developing personalised therapy for prostate cancer.
format Online
Article
Text
id pubmed-3670502
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-36705022014-05-28 Patient-reported genitourinary toxicity for long-term prostate cancer survivors treated with radiation therapy Olsson, C E Pettersson, N Alsadius, D Wilderäng, U Tucker, S L Johansson, K-A Steineck, G Br J Cancer Clinical Study BACKGROUND: The objective of this study is to provide comprehensive overviews of patient-reported urinary symptoms for long-term prostate cancer survivors treated with radiation therapy and for untreated, healthy men. METHODS: We performed a population-based cross-sectional study using a study-specific postal questionnaire assessing symptoms among 1007 men consecutively treated at the Sahlgrenska University Hospital, Göteborg, Sweden from 1993–2006 (primary or salvage external beam radiation therapy (EBRT) or EBRT and high-dose rate brachytherapy). We also randomly recruited 350 non-pelvic-irradiated matched control men from the Swedish Total Population Register. Symptom prevalence and prevalence ratios were computed. RESULTS: Survey participation rate was 89% (874/985) for eligible survivors and 73% (243/332) for eligible controls. Median time from treatment to follow-up was 5 years (range, 1–14 years). Among the 21 investigated symptoms reflecting obstruction, frequency, urgency, pain and incontinence, we found significantly higher prevalence compared with controls for 9 symptoms in the EBRT group, 10 in the EBRT+brachytherapy group and 5 in the salvage EBRT group. The prevalence for a majority of the symptoms was stable over time. CONCLUSION: The presented toxicity profiles provide a thorough understanding of patient-reported urinary symptoms that can assist in developing personalised therapy for prostate cancer. Nature Publishing Group 2013-05-28 2013-04-30 /pmc/articles/PMC3670502/ /pubmed/23632483 http://dx.doi.org/10.1038/bjc.2013.180 Text en Copyright © 2013 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/3.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
spellingShingle Clinical Study
Olsson, C E
Pettersson, N
Alsadius, D
Wilderäng, U
Tucker, S L
Johansson, K-A
Steineck, G
Patient-reported genitourinary toxicity for long-term prostate cancer survivors treated with radiation therapy
title Patient-reported genitourinary toxicity for long-term prostate cancer survivors treated with radiation therapy
title_full Patient-reported genitourinary toxicity for long-term prostate cancer survivors treated with radiation therapy
title_fullStr Patient-reported genitourinary toxicity for long-term prostate cancer survivors treated with radiation therapy
title_full_unstemmed Patient-reported genitourinary toxicity for long-term prostate cancer survivors treated with radiation therapy
title_short Patient-reported genitourinary toxicity for long-term prostate cancer survivors treated with radiation therapy
title_sort patient-reported genitourinary toxicity for long-term prostate cancer survivors treated with radiation therapy
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3670502/
https://www.ncbi.nlm.nih.gov/pubmed/23632483
http://dx.doi.org/10.1038/bjc.2013.180
work_keys_str_mv AT olssonce patientreportedgenitourinarytoxicityforlongtermprostatecancersurvivorstreatedwithradiationtherapy
AT petterssonn patientreportedgenitourinarytoxicityforlongtermprostatecancersurvivorstreatedwithradiationtherapy
AT alsadiusd patientreportedgenitourinarytoxicityforlongtermprostatecancersurvivorstreatedwithradiationtherapy
AT wilderangu patientreportedgenitourinarytoxicityforlongtermprostatecancersurvivorstreatedwithradiationtherapy
AT tuckersl patientreportedgenitourinarytoxicityforlongtermprostatecancersurvivorstreatedwithradiationtherapy
AT johanssonka patientreportedgenitourinarytoxicityforlongtermprostatecancersurvivorstreatedwithradiationtherapy
AT steineckg patientreportedgenitourinarytoxicityforlongtermprostatecancersurvivorstreatedwithradiationtherapy